Gemcitabine, vinorelbine and prednisone for refractory or relapsed aggressive lymphoma,results of a phase II single center study |
| |
Authors: | Hannes Müller-Beißenhirtz Christoph Kasper Holger Nückel Ulrich Dührsen |
| |
Institution: | 1. Klinik für H?matologie, Universit?tsklinikum Essen, Hufelandstrasse 55, 45122, Essen, Germany
|
| |
Abstract: | The optimum therapy for patients with relapsed or refractory aggressive non-Hodgkin’s lymphomas (NHL) not qualifying for platinum-based
and/or high-dose chemotherapy is not known. We conducted a prospective phase II study evaluating a regimen consisting of gemcitabine
(1 g/m2, days 1 and 8), vinorelbine (30 mg/m2, days 1 and 8) and prednisone (100 mg/day, days 1–8) (GVP) given every 21 days. Fifteen patients with a median age of 68
years and a median of three previous therapies were enrolled. Diagnoses included B lymphoblastic (n=1), diffuse large B cell (n=10), anaplastic large T cell (n=2) and peripheral T-cell NHL (n=2). The median international prognostic index score was 3 (six patients with a score of 4 or 5). Five patients achieved a
complete remission and three patients a partial remission. The median overall survival was 13.8 months, and the median time
to next treatment was 4.4 months. Haematological toxicities of World Health Organisation grades 3/4 were leucopenia in 58%,
thrombocytopenia in 33% and anaemia in 17% of all courses. Three patients had grade 3 infections. There was no treatment-related
mortality. GVP shows substantial activity in poor prognosis relapsed or refractory aggressive lymphomas and is generally well
tolerated, but haematological toxicity is dose limiting. |
| |
Keywords: | Aggressive lymphoma Gemcitabine Vinorelbine Salvage therapy Phase II trial |
本文献已被 PubMed SpringerLink 等数据库收录! |
|